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Abstract
Introduction: Rheumatoid arthritis (RA) is the most common inflammatory joint disease in adults with a prevalence of 0.5–1%. The
development of targeted therapies, especially anti-TNF (tumor necrosis factor) treatment, has improved disease outcome during the last
decade. But despite this progress 25–30% of patients still show unsatisfactory response. Abatacept is a costimulation blocker that
inhibits T-cell activation and interrupts the process that leads to inflammation in RA.
Aims: The purpose of this article is to review the clinical trials of abatacept and to discuss how it will fit into the treatment of RA. The
medical literature was reviewed for appropriate articles and 123 articles have been identified containing the search terms "abatacept OR
CTLA4-Ig AND rheumatoid." All clinical trials were reviewed with respect to clinical and radiologic outcome, quality of life, and safety of
patients with RA receiving abatacept therapy.
Evidence review: There are seven (phase II or phase III) clinical trials that have clearly demonstrated efficacy and safety of this new
drug. Furthermore, radiographic data show that abatacept also inhibits the progression of joint destruction, one of the important burdens
of RA. Abatacept can be used concomitantly with conventional disease-modifying antirheumatic drugs or as monotherapy. Due to an
increased risk of infections and malignancies but without an important enhancement of efficacy, simultaneous treatment with abatacept
and other biologic response modifiers is not recommended.
Place in therapy: With its different mechanism of action, abatacept may be an alternative therapy for patients with an inadequate
response to other arthritis therapies, especially for those patients with RA refractory to anti-TNF treatment. Cost effectiveness is
dependent on underlying disease progression.
Core Evidence. 2007;2(3):163–172.
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Core evidence place in therapy summary for abatacept in rheumatoid arthritis
Outcome measure Evidence Implications
Patient-oriented evidence
Reduction of pain Clear Significant improvement of pain on Visual Analog Scale
Increase of joint function Clear Increase of Health Assessment Questionnaire scores
Increase of QOL Clear Improvement of physical and mental health
Disease-oriented evidence
Reduction of synovitis Clear Improvement of swollen and tender joint count
Reduction of disease progression Clear Decrease of radiographic joint damage
Reduction of inflammatory response Clear Decrease of C-reactive protein levels and biomarkers
Economic evidence
Cost effectiveness Limited  Costs per patient and per year comparable to other biologics. Cost
effectiveness driven by assumptions made for disease progression
QOL, quality of life.Scope, aims, and objectives
Abatacept (Orencia®, Bristol-Myers Squibb) is a drug used in
targeted therapy of rheumatoid arthritis (RA). It exerts an
antiinflammatory action by the inhibition of T-cell activation. Its
use is recommended for treatment-resistant patients with RA after
ineffective therapy with one or more disease-modifying
antirheumatic drugs (DMARDs). After an initial loading period of
three intravenous infusions every other week, abatacept is given
every 4 weeks. Several clinical trials have demonstrated the
efficacy of this new drug. Furthermore, radiographic data show
that abatacept also slows the progression of joint destruction, one
of the important burdens of RA. The purpose of this article is to
review the clinical trials of abatacept and to discuss how it will fit
into the treatment of RA.
Methods
The medical literature was reviewed for appropriate articles
relating to abatacept on PubMed (http://www.ncbi.nlm.nih.gov)
using the search terms "abatacept OR CTLA4-Ig AND
rheumatoid." The search was updated on June 18, 2007. One
hundred and twenty-three articles were found, of which 12 
were written in languages other than English and were
excluded. Within those 111 publications, 12 reports from clinical
trials and 45 review articles have been identified. Out of the
reports from clinical trials, 11 are included and also cited in 
this review (Table 1). The excluded clinical trial article was 
out of scope as its aim was to compare health assessment 
scales. In addition, one abstract has been published presenting 
clinical data, which is included in the Place in therapy 
section. Thirty-four further abstracts were identified from the
European League Against Rheumatism (EULAR) 2007 congress
(http://www.abstracts2view.com/eular), of which 10 were
considered relevant.
The results of the included clinical trials are reviewed, focusing on
clinical and radiologic efficacy, quality of life, and safety of
abatacept in patients with RA. There are seven phase II and III
clinical trials, and a further four reports show data not of primary
endpoints derived from these trials. No pharmacoeconomic
studies of abatacept in RA were identified.
Disease overview
RA is the most common inflammatory joint disease in adults with
a prevalence of 0.5–1%. The disease has a worldwide distribution
and affects all ethnic groups at any age; its prevalence increases
with age with an incidence maximum between the fourth and
sixth decade. Both genders are affected but two-thirds of patients
are female (Gabriel 2001).
Epidemiologic studies and clinical trials are based on the
classification criteria of the American College of Rheumatology
(ACR) for RA (Arnett et al. 1988). Signs and symptoms, namely
joint swelling and pain, are caused by an inflammation of the
synovial membrane. This multifactorial autoimmune process is
triggered by unknown causes and mediated by a complex
cascade of cellular and humoral (inter)actions. The migration of
leukocytes into the joints and the activation of osteoclasts results
in synovitis and bone erosions (Redlich et al. 2002). There is
increasing evidence that this damage and its functional
consequences occur early in the course of the disease. Several
studies show that 39–73% of patients develop erosions in their
hands and wrists within 5 years. After 20 years RA patients have
on average 43% of maximum possible damage and only 25% are
still nonerosive at this time (Scott 2004). A common goal is early
and aggressive therapy to achieve better prognosis of this chronic
disease (Quinn et al. 2001; Quinn & Emery 2005; Smolen et al.
2005a). Extraarticular manifestations can include rheumatoid
nodules, vasculitis, episcleritis, pulmonary fibrosis,
lymphadenopathy, or fever. Furthermore, the chronic
inflammatory response is associated with an elevated risk of
osteoporosis, cardiovascular events, infections, secondary
amyloidosis, or lymphoproliferative malignancies. Several studies
demonstrate an increased mortality in patients with RA, with a
standardized ratio between 1.28 and 2.98. The disease reduces
life expectancy by 7 years for men and 3 years for women (Mikuls
& Saag 2001).
Current therapy options
Although the causes of RA are still not completely elucidated,
several pathways and mechanisms in the perpetuation of
inflammation have been well characterized. Over the last two
decades, advances in the knowledge of molecular biologic
techniques have led to a better understanding of
immunopathogenesis, which propagates chronic arthritis (Smolen
et al. 2004, 2005b). The complex network of cellular and humoral
interactions opens up a broad spectrum of potential therapeutic
targets. Continued research toward new and better-tolerated
therapies to attenuate the inflammation and pain associated with
RA and to halt the progression of erosive joint damage has led to
the development of strategies blocking cytokines or modulating
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Category Number of records
Full papers Abstracts
Initial search 123 34
records excluded 66 24
records included 57 10
Additional studies identified 0 1
Total records included 11 11
Level 1 clinical evidence
(systematic review, meta analysis)
01
Level 2 clinical evidence (RCT) 7 6
Level ≥3 clinical evidence 0 3
trials other than RCT
case reports
Economic evidence 0 1
For definitions of levels of evidence, see Editorial Information on inside back cover or on
Core Evidence website. 
RCT, randomized controlled trial.
Table 1 | Evidence base included in the review 165
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the costimulation of immune cells. Such agents are called
"biologics,” an abbreviated colloquial term for “biologic response
modifiers” (Köller 2006).
Beside nonsteroidal antiinflammatory drugs (NSAIDs) and
corticosteroids, DMARDs such as methotrexate, sulfasalazine,
leflunomide, cyclosporin A, azathioprine, and (hydroxy-)
chloroquine are essential and therefore used to reduce synovitis.
A number of biologic agents have been developed to target
different immune markers or mediators with the hope that they
may help to control the inflammation in patients who are resistant
to treatment with conventional DMARDs. Especially in adult RA,
several biologic agents targeting different mediators, like tumor
necrosis factor (TNF)-alfa, interleukin (IL)-1, and IL-6, have been
investigated in clinical trials (Table 2). Also targeting 
B lymphocytes decreases disease avtivity of RA (Edwards et al.
2004; Köller 2006).
The approach to the treatment of RA has changed in the last 
10 to 15 years. In most cases conventional DMARDs are the 
first-choice therapy of established RA. Methotrexate, if 
not contraindicated, remains the gold standard in this
armamentarium. Other drugs, namely sulfasalazine or 
leflunomide, have been demonstrated to be of equal potency.
However, TNF-alfa-blocking agents have particularly improved
outcomes in RA treatment and therefore their use has been
investigated in early stages of disease. It has been shown that
anti-TNF therapy, particularly in combination with methotrexate at
the beginning of treatment, is superior in improving clinical
outcome and preventing radiologic damage compared with
methotrexate treatment alone in patients with highly active
disease (Genovese et al. 2002; Breedveld et al. 2006). However,
in general up to 25% of patients fail to respond adequately to TNF
blockade or develop loss of efficacy, therefore new therapy
options are still required (Keystone & Kavanaugh 2005).
Evidence from different experimental approaches suggest that 
T cells play an important role in the pathogenesis of RA (Goronzy
& Weyand 2004; Skapenko et al. 2005). Another therapeutic
option is to block cellular interactions, namely costimulatory
signals which are essential for the stimulation of T lymphocytes.
One of these signals is induced by the interaction of CD80/86 on
antigen-presenting cells (APCs) and CD28 on T cells. Cytotoxic 
T-lymphocyte-associated protein 4 (CTLA4) is a protein
homologous to CD28, which is expressed mainly by activated 
T cells. It competes with CD28 for binding to CD80/CD86 with a
much higher affinity for these ligands, and provides a negative
feedback loop (Sfikakis & Via 1997).
Abatacept is a soluble fusion protein consisting of the
extracellular domain of human CTLA4 and an Fc-fragment of an
immunoglobulin (Ig), namely IgG1. By binding to CD80 and
CD86 ligands on the APCs it prevents a costimulatory signal by
CD28 (Dumont 2004). The ability of CTLA4-Ig to block T-cell-
dependent primary and secondary immune responses has been
demonstrated in murine and primate models (Webb et al. 1996;
Quattrocchi et al. 2000).
Clinical evidence for abatacept in rheumatoid
arthritis
Experimental data from animal models have demonstrated that
the administration of CTLA4-Ig ameliorates collagen-induced
arthritis in mice (Knoerzer et al. 1995). Thereafter, several clinical
trials have shown biologic effects and proven the efficacy of
abatacept in the treatment of RA in humans.
The pharmacokinetic parameters of abatacept were studied in
healthy volunteers who received a single 10 mg/kg dose or
patients with RA who received multiple doses. The
pharmacokinetic parameters in these two populations were
comparable, with a mean a half-life of 13.1 days (range 
8–25 days). No accumulation was seen after monthly repeated
infusions. A slightly increased clearance was observed with
increasing bodyweight, but no age or sex differences were
noted, which finally led to the recommendations of dose
adjustment to bodyweight (Moreland et al. 2002).
At the doses of 2 mg/kg or 10 mg/kg used in further clinical
studies, abatacept decreased serum levels of proinflammatory
cytokines and inflammatory responses, including soluble IL-2
receptor, IL-6, E-selectin, TNF-alfa, rheumatoid factor, and 
C-reactive protein levels (Weisman et al. 2006). Although
abatacept inhibits T-cell function it does not deplete T cells
(Kremer 2004).
Clinical efficacy assessment
Clinical efficacy and current disease activity can be measured in
several ways using different scores. Response criteria according
to the ACR allow judging improvement or change from baseline
but not the actual state of disease activity. An ACR20, 50, or 70
response is defined as a 20%, 50%, or 70% reduction in the
number of swollen and tender joints, as well as some other 
core sets of laboratory parameters or quality-of-life settings 
(Table 3).
Mechanism Target 
molecule(s)
Therapeutic
agent
Molecule
structure
TNF blockade mTNFα + sTNFα
sTNFα
mTNFα + sTNFα
Infliximab
Etanercept
Adalimumab
Chimeric mab
TNFR2-Ig
Human mab
IL-1 receptor
blockade
IL-1R Anakinra Human IL-1RA
B-cell depletion CD20 Rituximab Chimeric mab
Costimulation
blockade
CD80/CD86 Abatacept CTLA4-Ig
IL-6 receptor
blockade
IL-6R Tocilizumab Human mab
CTLA4, cytotoxic T-lymphocyte-associated protein 4; Ig, immunoglobulin; IL-1(RA),
interleukin-1(receptor antagonist); IL-6(R), interleukin-6(receptor); mab, monoclonal
antibody; (m/s)TNF(R), (membrane/soluble) tumor necrosis factor (receptor).
Table 2 | Biologic disease-modifying antirheumatic drugs
currently available or in phase III trialsAdditional outcome measures commonly used mainly in clinical
practice include the Disease Activity Score (DAS)-28, which is
calculated using tender and swollen joint count out of 28 joints
investigated, erythrocyte sedimentation rate, as well as estimation
of disease activity by the patient on a 100 mm Visual Analog Scale
(VAS), which provides a continuous measure of disease activity. A
DAS-28 score of <2.6 indicates remission, ≤3.2 indicates low
disease activity, while scores of ≥5.1 define high disease activity
(Prevoo et al. 1995).
Patients with RA not only suffer from pain, stiffness, swelling, and
joint destruction, but also with loss of physical function.
Therefore, assessment of disability and health status reflecting
patients’ quality of life is also a pivotal aspect in any therapeutic
trial. The instrument most frequently used for evaluating
functional impairment is the Health Assessment Questionnaire
Disability Index (HAQ-DI), while health status is most often
evaluated by the Medical Outcomes Study Short Form (SF)-36
(Doyle 2001).
Prevention of joint destruction which may not be reversible is one
of the key desired effects of treatment with new antiinflammatory
drugs. Joint space narrowing and bone erosions evaluated on
plain joint radiographs reflect the grade of joint damage. The most
often-used assessment tools for evaluating joint destruction is 
the Sharp score and its modifications (Pincus et al. 1997; 
Lassere 2000). 
Clinical efficacy in phase II and III trials
Abatacept was approved by the Food and Drug Administration
(FDA) on December 23, 2005 for reducing the signs and
symptoms of moderate to severe RA in adult patients who have
had an inadequate response to at least one DMARD (FDA 2005).
The main basis for this decision included phase II and phase III
randomized, double-blind, placebo-controlled trials in adult RA
patients showing data over a treatment period of 6 or 12 months.
In a phase IIb, multicenter, international study two dosages of
abatacept (2 mg/kg and 10 mg/kg) were compared in patients
with RA who had active disease despite methotrexate therapy.
Abatacept was given intravenously over 30 min on day 1, 15, 30,
and every 4 weeks thereafter for 6 months. In total 339 patients
were treated, of whom 119 were assigned to placebo, another
105 received the low dosage, and 115 were treated with the
higher dose, all of them while continuing methotrexate. Sixty
percent of the patients in the 10 mg/kg group achieved an ACR20
response, compared with 41.9% in the lower dose group and in
35.3% of the placebo-treated patients (Kremer et al. 2003).
Evaluation of ACR50 and ACR70 responses also favored the
higher dosage, although both dosages of abatacept were
significantly better than placebo (Table 4). There was no
significant difference in ACR20 response rates between the 
2 mg/kg dosage group and placebo patients.
An extension of this study revealed similar results after 12 months
of treatment (Kremer et al. 2005). At day 360, 62.6% in the 
10 mg/kg group showed an ACR20 response versus 36.1% in the
placebo group (P<0.001). No significant differences were found
between abatacept 2 mg/kg and placebo, whereas improvement
in ACR50 and ACR70 was significantly greater with abatacept 
10 mg/kg (Table 5). The higher dose of abatacept also showed
significantly higher improvement in quality-of-life parameters,
whereas the 2 mg/kg group showed a very weak and transient
response (Emery et al. 2006). These results confirm that
abatacept 2 mg/kg is suboptimal for effective treatment of 
active RA.
The Abatacept Trial in the Treatment of Anti-TNF Inadequate
Responders (ATTAIN) investigated the efficacy of abatacept in
patients with RA who failed anti-TNF therapy either with
etanercept or infliximab (Genovese et al. 2005). Patients had to be
on anti-TNF-alfa treatment for at least 3 months before entering
the study. Two groups were enrolled: “current users” who were on
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Swollen joint count (66 joints)
Tender joint count (68 joints)
Subject global assessment of pain (VAS 100 mm)
Subject global assessment of disease activity (VAS 100 mm)
Physician global assessment of disease activity (VAS 100 mm)
Subject assessment of physical function using HAQ
C-reactive protein
The ACR20 (50, 70) definition of response specifies a 20% (50%, 70%) improvement over
baseline in swollen and tender joints and in 3/5 of the remaining core data set measures.
HAQ, Health Assessment Questionnaire; VAS, Visual Analog Scale.
Table 3 | American College of Rheumatology disease-response
criteria (Felson et al. 1995) 
Abatacept 
2 mg/kg (%)
Abatacept 
10 mg/kg (%)
Placebo
(%)
ACR20 response 41.9 (P=0.31; NS) 60.0 (P<0.001) 35.3
ACR50 response 22.9 (P<0.05) 36.5 (P<0.001) 11.8
ACR70 response 10.5 (P<0.05) 16.5 (P<0.001) 1.7
The ACR20 (50, 70) definition of response specifies a 20% (50%, 70%) improvement over
baseline in swollen and tender joints and in 3/5 of the remaining core data set measures.
NS, not significant.
Table 4 | Response to abatacept or placebo after 6 months 
in patients with active rheumatoid arthritis despite
methotrexate treatment (percentage of patients)
(Kremer et al. 2003)
Abatacept 
10 mg/kg (%)
Placebo (%) P value
ACR20 response 62.6 36.1 <0.001
ACR50 response 41.7 20.2 <0.001
ACR70 response 20.9 7.6 <0.001
The ACR20 (50, 70) definition of response specifies a 20% (50%, 70%) improvement over
baseline in swollen and tender joints and in 3/5 of the remaining core data set measures.
Table 5 | Response to abatacept or placebo after 1 year in
patients with active rheumatoid arthritis despite
methotrexate treatment (percentage of patients)
(Kremer et al. 2005)167
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anti-TNF treatment at the time of screening, and “former users”
who had previously received such therapy. Wash-out periods were
≥28 days for etanercept and ≥60 days for infliximab. All patients
stayed on concomitant immunosuppressive therapy with an oral
conventional DMARD (mostly methotrexate) or anakinra (Table 6).
Two hundred and fifty-six patients were randomly assigned to
abatacept (approximately 10 mg/kg) in a double-blind fashion.
Patients with bodyweight <60 kg received 500 mg, those
weighing 60 to 100 kg received 750 mg, and patients weighing
>100 kg were treated with 1000 mg of abatacept, which are also
the doses now recommended for clinical use. The initial dose
was followed by repeat doses 2 and 4 weeks later and every 
4 weeks thereafter (Bristol-Myers Squibb 2005). One hundred
and thirty-three patients were included in the placebo arm. After
6 months, 233 of the abacept group and 99 of those on placebo
finished the double-blind period, of whom 317 entered an open-
label extension with abatacept treatment following the dosage
schedule described above.
Primary endpoints were percentage of patients achieving an
ACR20 response and a significant improvement (≥0.3 unit) in
HAQ-DI score. Secondary endpoints included percentage of
patients achieving ACR50 and ACR70 responses, remission
according to DAS-28 (≤2.6), low disease activity (DAS-28, ≤3.2),
and changes in health-related quality of life assessed by SF-36.
Additionally, the question of safety issues was addressed.
Patient demographics are given in Table 7. Two-thirds of the
patients were treated with infliximab and one-third with
etanercept before randomization. After a protocol amendment,
some patients with treatment failure of adalimumab also entered
the study.
After 6 months one-half of the patients treated with abatacept
achieved an ACR20 response. In contrast this was observed only
in approximately 20% of the patients receiving placebo.
Significant differences were also observed for ACR50 and
ACR70 responses as well as low disease activity or remission
according to the DAS-28 (Fig. 1). At the end of the blinded study
phase after 6 months, significantly more patients achieved low
disease activity or remission with abatacept than with placebo
(Fig. 2).
After 18 months of abatacept treatment (1 year in the open
extension phase of the study) the percentage of patients who
achieved remission significantly increased up to 22.5%, 10% of
whom had been in remission after 6 months. Furthermore, 20.6%
of the patients of the former placebo group achieved remission of
disease after 1 year of abatacept treatment; only 0.8% of these
patients had been in remission at the end of the 6-month
blinded placebo period. Almost 40% in both groups showed low
disease activity after 18 months of treatment. Furthermore,
quality of life as evaluated by HAQ-DI and SF-36 revealed a
significantly greater improvement with abatacept treatment
compared with placebo (Westhovens et al. 2006); the beneficial
effects of abatacept on psychologic wellbeing were further
confirmed in an observational evaluation of a small subset of
study participants (Hassett et al. 2007). After 2 years of
abatacept treatment, the percentage of patients reporting
severe fatigue, pain, and sleep problems was reduced from
68%, 58%, and 13%, to 29%, 9%, and 4%, respectively
(Dougados et al. 2007a), which contributes to perceptions of
quality of life. These beneficial changes in patient-reported
outcomes correlated with improved ability to participate in
normal daily actvities (Wells et al. 2007).
The 1-year, phase III, Abatacept in Inadequate Responders to
Methotrexate (AIM) trial was designed to further evaluate the
safety and clinical efficacy of abatacept in combination with
methotrexate, and to assess the effects of abatacept on the
radiographic progression of structural damage (Kremer et al.
DMARD Abatacept (%) (n=256) Placebo (%) (n=133)
Methotrexate 75.6 82.0
Leflunomide 8.9 8.3
Sulfasalazine 7.0 9.8
Azathioprine 2.7 2.3
Hydroxychloroquine 8.9 9.0
Chloroquine 0.0 0.8
D-penicillamine 0.4 0.0
Gold salts 0.0 0.8
Anakinra 2.7 2.3
DMARD, disease-modifying antirheumatic drug.
Table 6 | Concomitant DMARD therapy in the ATTAIN trial
(Abatacept Trial in the Treatment of Anti-TNF
Inadequate Responders) (Genovese et al. 2005)
Abatacept (n=256) Placebo (n=133)
Age (years) 53.4 52.7
Female (%) 77.1 79.7
Mean duration of RA (years) 12.2 11.4
Rheumatoid factor-positive (%) 73.3 72.9
Anti-TNF current/former (%) 38.0/62.0 41.4/58.6
etanercept 32.2 39.8
infliximab 67.8 60.2
adalimumab 2.3 1.5
Swollen joint count 22.3 22.3
Tender joint count 31.2 32.8
Pain (VAS in mm) 70.8 69.9
DAS-28 6.5 6.5
C-reactive protein (mg/dL) 4.6 4.0
DAS, Disease Activity Score; RA, rheumatoid arthritis; TNF, tumor necrosis factor; VAS,
Visual Analog Scale.
Table 7 | Patient demographics in the ATTAIN trial (Abatacept
Trial in the Treatment of Anti-TNF Inadequate
Responders) (Genovese et al. 2005)2006). In this multicenter, randomized, double-blind, placebo-
controlled trial 656 patients with active RA despite methotrexate
therapy were assigned in a ratio of 2:1 to additional treatment
with abatacept (approximately 10 mg/kg) or placebo. Dosage
was identical to that in the ATTAIN trial. The study medication
was given intravenously on days 1, 15, and 29 and then every 
4 weeks up to 337 days. The dosage of methotrexate had to be
15 mg or more per week, although methotrexate 10 mg per
week was acceptable if the patient had a history of toxicity.
Three hundred and eighty-five patients in the abatacept group
and 162 patients receiving placebo finished 12 months of study
treatment. The three primary outcome measurements were the
percentage of patients with an ACR20 response after 6 months,
the percentage of patients with a significant improvement 
(≥0.3 unit) in the HAQ-DI at 1 year, and the radiographic
progression of joint erosions (assessed by comparing changes
from baseline in the Genant-modified Sharp score) at 1 year.
Secondary objectives included ACR50 and ACR70 responses at
6 months and all ACR responses at 1 year. In addition, the
proportions of patients achieving a major clinical response at 
1 year were analyzed. Furthermore, changes in disease activity
by using the DAS-28 and changes in health-related quality of life
using the SF-36 were evaluated.
More patients in the abatacept group (89%) than in the placebo
group (74%) completed 1 year of treatment. There were no
differences in the mean dosage of methotrexate between
groups. In an intention-to-treat analysis, an ACR20 response
was achieved in 67.9% of the patients treated with abatacept
compared with 39.7% under placebo (P<0.001). Similarly,
ACR50 and ACR70 response rates were significantly higher in
abatacept-treated patients (Fig. 3).
Between 6 and 12 months, all ACR responses continually
improved in patients receiving abatacept, but not so under
placebo treatment. At 1 year, ACR20 responses had increased
to 73.1% versus 39.7%, ACR50 responses were 48.3% versus
18.2%, and ACR70 responses were 28.8% versus 6.1% after
treatment with abatacept versus placebo, respectively
(P<0.001). Percentages of patients with ACR50 and ACR70
responses significantly increased from 6 to 12 months
(P<0.001). Of the patients with ACR20 after 6 months, 42.9% of
those receiving abatacept achieved ACR50 after 1 year
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Fig. 3 | ACR response after 1 year of abatacept versus placebo
in methotrexate-resistant rheumatoid arthritis (AIM trial)
(Kremer et al. 2006). The ACR20 (50, 70) definition of
response specifies a 20% (50%, 70%) improvement over
baseline in swollen and tender joints and in 3/5 of the
remaining core data set measures
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Fig. 2 | Low disease activity and remission after 6 months of
abatacept or placebo treatment following anti-TNF failure
in patients with rheumatoid arthritis (ATTAIN trial)
(Genovese et al. 2005). TNF, tumor necrosis factor
(reproduced from Genovese MC et al. N Engl J Med.
2005;353:1114-1123. Copyright © 2005 Massachusetts
Medical Society. All rights reserved)
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Fig. 1 | ACR response after 6 months of abatacept versus
placebo following failure of anti-TNF therapy in patients
with rheumatoid arthritis (ATTAIN trial) (Genovese et al.
2005). ACR, American College of Rheumatology; 
TNF, tumor necrosis factor (reproduced from Genovese
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compared with 14.3% of placebo recipients, and 21% versus
2% improved to ACR70 (Dougados et al. 2007b).
Physical function significantly improved after 1 year in more
patients receiving treatment with abatacept than placebo (63.7%
vs 39.3%; P<0.001). Baseline disease activity was at similar high
levels in both groups (DAS-28, 6.4). At 6 and 12 months, 30.1%
and 42.5% of the abatacept group, respectively, had a DAS-28 of
≤3.2 (i.e. low disease activity), compared with 10.0% and 9.9% of
the placebo group, respectively (P<0.001). Abatacept induced a
DAS-28 score of <2.6 (i.e. disease remission) in 14.8% of
patients, whereas this was observed in 2.8% of the patients
receiving placebo at 6 months and in 23.8% versus 1.9% at 1
year (P<0.001). Remission was observed after 1 year in 35.6% of
the abatacept group who achieved a DAS-28 score of ≤3.2 after
6 months, in contrast to none of the placebo group (Dougados et
al. 2007b). 
Combined abatacept and methotrexate treatment leads to
significant improvements across a wide range of quality-of-life
domains in patients with RA (Russell et al. 2007). In a similar
pattern to the ATTAIN trial, 2 years of treatment with abatacept
decreased the proportion of patients with fatigue, pain, and sleep
problems (Dougados et al. 2007a).
Radiologic data
The 1-year analysis of the AIM trial also included radiographic
outcome. Baseline erosion, joint space narrowing, and total
scores were similar between the groups, and after 12 months
abatacept-treated patients revealed significantly less progression
compared with placebo recipients. The median change from
baseline in erosion score was 0 for abatacept versus 0.27 for
placebo (P=0.029). The median change in total score was 0.25
with abatacept versus 0.53 with placebo (P=0.012). The mean
change from baseline was 0.63 with abatacept versus 1.14 with
placebo in erosion score, 0.58 with abatacept versus 1.18 with
placebo in joint space narrowing score, and 1.21 with abatacept
versus 2.32 with placebo in total score (Kremer et al. 2006).
Safety, tolerability, and combination with other DMARDs 
Inhibiting T-cell activation raises concerns over the host’s
defense against malignancies or infections. Safety issues have
been addressed in all phase II and III clinical trials as secondary
endpoints. The overall frequency of malignancies was similar in
abatacept- and placebo-treated patients (1.3% vs 1.1%,
respectively) (Bristol-Myers Squibb 2005). During placebo-
controlled study phases there have been four cases of lung
cancer (0.2%) during abatacept treatment, compared with none
under placebo. Including open extension studies, 1955 patients
were treated with abatacept until February 2005. In this cohort,
eight cases of lung cancer (0.21 per 100 patient-years) and four
cases of lymphoma (0.10 per 100 patient-years) have been
recorded (Bristol-Myers Squibb 2005). The observed number of
lung cancer cases is approximately twice what would be
expected based on the US general population incidence rates.
The expected number of lung cancer events in the RA cohorts
ranged from 3.6 to 9.9. Patients with RA, particularly with active
disease, are two to four times more likely to develop lymphoma
than the general population. However, an epidemiologic study
found that the overall incidence rates of malignancy, lung
cancer, and lymphoma among 4134 abatacept-treated patients
did not differ significantly from those in six cohorts of over 
94000 RA patients exposed to nonbiologic DMARDs (Simon et
al. 2007a). 
The same authors reported that the incidence rates of serious
infection with abatacept were similar to those in RA patients
taking nonbiologic DMARDs (Simon et al. 2007b). In the placebo-
controlled trials infections were observed in 54% versus 48% in
abatacept- and placebo-treated groups, and serious infection
rates were 3.0% and 1.9%, respectively (Bristol-Myers Squibb
2005). Level 1 evidence (published as an abstract) from a meta
analysis of five RCTs on abatacept involving a total of 1960
patients did not reveal a significant increase in the frequency of
serious infection compared with placebo (Salliot et al. 2007). 
The Abatacept Study of Safety in Use with Other RA Therapies
(ASSURE) was designed to assess as a primary objective the
safety of abatacept compared with placebo when added to
therapy with one or more conventional or biologic DMARDs
(Weinblatt et al. 2006). Patients were treated for 1 year in a
double-blind, placebo-controlled trial, and the dosage regimen of
abatacept was adjusted to bodyweight according to the protocol
of the ATTAIN trial. All patients had to continue their “background”
DMARD therapy. Secondary endpoints were clinical outcome
measures. After 1 year, 836 patients treated with abatacept and
395 patients treated with placebo finished the study, most of
whom were on combination with nonbiologic therapies. Almost
13% of the patients in the abatacept group and 18% of the
placebo group discontinued treatment before the end of the
study. Overall adverse events (90% and 87%, respectively) and
serious adverse events (13% and 12%, respectively) were similar
for abatecept and placebo. Death occurred in five (0.5%)
abatacept- and four (0.8%) placebo-treated patients.
However, in the smaller group of patients on background biologic
therapies there was an increase in serious adverse events (22.3%
vs 12.5%) and serious infections (2.9% vs 1.9%) observed in
patients on abatacept compared with placebo. This suggests that
the safety profile for patients receiving background DMARDs
appears favorable over 1 year but is less so in those patients on
background biologic therapies.
A recent subanalysis of the phase IIIb ARRIVE (Abatacept
Researched in Rheumatoid Arthritis Patients with an Inadequate
Response to Validate Effectiveness) trial indicates that a wash-out
period is not required before initiating abatacept in patients who
have failed anti-TNF treatment (Schiff et al. 2007). The frequency
of adverse events (including those of a serious nature), infection,
neoplasm, drug discontinuation, or death were not significantly
different between patients who had stopped anti-TNF medication
≥2 months prior to starting abatacept (n=370) and those who had
received anti-TNF therapy within 2 months of starting abatacept
(n=472).Experimental data from animal models suggest that the
combination of biologic DMARDs may be beneficial (Zwerina et
al. 2005). In a recent trial 121 patients with active disease
despite etanercept therapy were randomized to receive
abatacept 2 mg/kg or placebo while continuing etanercept
(Weinblatt et al. 2007). On completion, data revealed only
marginal benefit of the combination (ACR20 and ACR50
responses after 6 months 48.2% and 30.6%, respectively, vs
placebo). No further major improvement was achieved by
increasing the abatacept dose to 10 mg/kg during the long-term
extension phase. Moreover, the rate of adverse events including
serious adverse events (16.5% vs 2.8%, respectively) as well as
serious infections (3.5% vs 0%, respectively) was significantly
higher in the combination therapy arm compared with placebo.
In summary, therefore, the combined use of abatacept and
biologic DMARD therapy is not recommended. 
Economic evidence
Pharmacoeconomic evidence on the use of abatacept in RA 
is limited. Using results from the AIM trial in a simulated
population of female patients aged 55 to 64 years with moderate
to severe RA and inadequate response to methotrexate, the cost
effectiveness of abatacept was estimated to be $US47910 per
quality-adjusted life-year (QALY) gained over a 10-year period,
and $US43 041 per QALY over a lifetime (Vera-Llonch et al.
2007). Abatacept was calculated to result in 1.2 additional
QALYs per patient for a mean cost of $US103601 compared
with $US52175 for methotrexate alone over 10 years, and two
additional QALYs at a cost of $US147853 versus $US80096 
over a lifetime.
An analysis conducted for the National Institute for Health and
Clinical Excellence (NICE) found that the incremental cost-
effectiveness ratio (ICER) of abatacept compared with
methotrexate was £25395, which is within a QALY threshold 
of  £30000 (NICE 2007). This estimate assumed disease
progression rates of 0.015 increases in HAQ score per year for
abatacept and 0.06 for methotrexate. Underlying disease
progression was indentified as the main driver of cost
effectiveness. Further analysis assuming a disease progression
rate of 0.03 for abatacept and 0.045 for methotrexate in HAQ
score found an ICER of £33567 per QALY, and £28445 with
corresponding rates of 0.03 and 0.06. The ICER for abatacept
increased to around £70000 if it was assumed that disease
progression was 0.012 with conventional DMARDs and 0.009
with abatacept.
Patient group/population
Abatacept is indicated for use in adult patients with moderately
to severely active RA who have had an inadequate response to
DMARDs including TNF antagonists, to inhibit the progression of
structural damage, improve physical function, and reduce signs
and symptoms of disease. It may be used as monotherapy or in
combination with other DMARDs. Concomitant use with TNF
antagonists if not recommended, although a wash-out period
before beginning abatacept does not appear to be required.
Prescribing information also states that caution should be
exercised when administering abatacept to elderly patients and
in those with active or a history of recurrent infections. Patients
should be screened for tuberculosis before beginning treatment
with immunomodulators such as abatacept.
Dosage, administration, and formulations
Abatacept should be given as a 30-min intravenous infusion at
a dose of 500 mg for patients with bodyweight <60 kg, 750 mg
in those weighing 60 to 100 kg, and 1 g in patients >100 kg. The
drug should be given 2 and 4 weeks after the first dose, then
every 4 weeks thereafter.
Abatacept is supplied as lyophilized powder for intravenous
infusion in single-use 250 mg vials.
Place in therapy for abatacept in rheumatoid
arthritis
Anti-TNF agents have improved the outcome of RA patients,
but there are still some unmet medical needs. Up to 25% of
patients treated with available biologic DMARDs show no
satisfactory response. There are essentially three options today
if, in addition to conventional DMARDs, therapy with a TNF
blocker has failed: (a) switch to another TNF blocker, which is
often successful; (b) deplete B cells by rituximab; and (c) block
costimulation with abatacept. Results from clinical trials show
that abatacept can be given as monotherapy or in combination
with other conventional DMARDs. Therefore, in December 2005
the FDA approved abatacept for the treatment of patients with
moderately to severely active RA who have had an inadequate
response to one or more DMARDs, such as methotrexate or
TNF antagonists. Similarly, on May 21, 2007 the European
Agency for the Evaluation of Medicinal Products approved
abatacept for the treatment of patients with moderately to
severely active RA who have had an inadequate response to at
least one TNF-blocking therapy or in case of contraindications
to anti-TNF therapy. At about the same time, the approved
indication for abatacept was updated by the FDA to include the
inhibition of structural damage progression.
The studies on abatacept (Table 8) show that ACR20 response
rates reach a plateau after 3 months of treatment, and the
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Reference Clinical trial
phase
Trial name Primary
outcome
Weinblatt et al. 2007 IIb – Safety
Weinblatt et al. 2006 III ASSURE Safety
Kremer et al. 2006 III AIM Efficacy
Genovese et al. 2006 III ATTAIN Efficacy
Kremer et al. 2005 IIb – Efficacy
Kremer et al. 2003 II – Efficacy
Moreland et al. 2002 II – Efficacy
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ACR50 and ACR70 responses seem to level off at 6 to 
8 months. Improvement appears to continue out to 1 year or
even longer. The radiographic data from the AIM trial
demonstrate a slowing of joint erosion by about 50% after 
1 year of abatacept treatment compared with placebo. Trials of
1- and 2-year duration with infliximab, etanercept, and
adalimumab have consistently shown less x-ray progression,
with joint erosion slowed on average by 80% to 90%. 
Abatacept seemed to exert comparable clinical efficacy
compared with infliximab after 6 months (Schiff et al. 
2006), with greater efficacy after 1 year as assessed by DAS-28
score and EULAR response criteria (Dougados et al. 2007c).
However, no radiographic data were reported in these
abstracts, and the dose of infliximab used (3 mg/kg every 
8 weeks) may have been suboptimal. In those patients with RA
refractory to anti-TNF treatment, response rates seem similar
under therapy with abatacept or rituximab, which has also 
been approved for anti-TNF-resistant RA patients (Smolen et 
al. 2007). While the combination of biologic response modifiers
is theoretically appealing and while animal data would argue for
this approach, clinical results have so far been disappointing. In
fact, no benefit could so far be shown with any combination,
while adverse events were increased in most cases. Although
no cases of tuberculosis have been observed so far, the fact 
that abatacept compromises T-cell immunity requires an 
adequate screening for latent infection before initiating 
therapy. Therefore, similar to anti-TNF therapy, patients 
with an increased risk for such infections should 
be excluded from abatacept treatment or monitored 
cautiously. A wash-out period in patients failing anti-TNF 
does not however appear to be necessary before
initiating abatacept.
Limited information was identified addressing the
pharmacoeconomic aspects of a treatment with abatacept. The
cost of abatacept is dependent on dosage; the recommendend
dosages for one infusion are 500 mg for patients <60 kg, 
750 mg for patient between 60 to 100 kg, and 1 g for patients
>100 kg. The annual cost per patient therefore ranges from
$US10105 to $US20210 depending on the dosage used
($US15158 for a 75 kg patient) and is comparable to other
biologics (National PBM 2006). The cost effectiveness of
abatacept in women unresponsive to methotrexate was
calculated to be $US43041 per QALY, which falls within the
threshold judged to be acceptable by many healthcare
providers. However, in October 2007 NICE in England and
Wales judged abatacept to be not cost effective in patients with
RA, despite an ICER of £25395 per QALY estimated from a
model based on the patient population in the ATTAIN trial.
In summary, abatacept is an effective drug for treating patients
with RA, and represents an interesting option especially for
those with an unsatisfactory response to anti-TNF therapy. It
appears to have a comparable cost and safety profile versus
other biologics, but as with other biologics, the physician needs
to monitor treatment carefully, particularly with respect to
malignancy and infection.
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